Jeffrey Joyce CV 11-8-12 - Kansas City University of Medicine and ...
Jeffrey Joyce CV 11-8-12 - Kansas City University of Medicine and ... Jeffrey Joyce CV 11-8-12 - Kansas City University of Medicine and ...
Jeffrey N. Joyce, Ph.D. December 2012dopamine D 3 receptor knock out mice but suppression by dopamine D 3 /D 2 antagonistsdoes not occur through the dopamine D 3 receptor. In Press, European Journal ofPharmacology, Volume 627, Issues 1-3, 10 February 2010, Pages 167-172 .5. Duka, T., Duka,V. Joyce, J.N. and Sidhu, A. Alpha-synuclein induces GSK-3β–catalyzed tau phosphorylation in Parkinson’s Disease models. FASEB J. 2009Sep;23(9):2820-2830.6. Kufah1, P.R. Zavala, A.R., Singh, A., Thiel, K.J., Dickey, E.D., Joyce, J.N.,Neisewander, J.L c-Fos expression associated with reinstatement of cocaine-seekingbehavior by response-contingent conditioned cues. Synapse. 2009 Oct;63(10):823-835.7. Zavala, A.R., Osredkar, T., Joyce, J.N. and Neisewander, J.L. Upregulation of ArcmRNA expression in the prefrontal cortex following cue-induced reinstatement ofextinguished cocaine-seeking behavior. Synapse, 2008 Jun;62(6):421-31.8. Mastroeni D, Grover A, Leonard B, Joyce JN, Coleman PD, Kozik B, Bellinger DL,Rogers J. Microglial responses to dopamine in a cell culture model of Parkinson'sdisease. Neurobiol Aging. 2009 Nov;30(11):1805-179. Lockhart, A., Lamb, J.R., Osredkar, T., Sue, L.I., Joyce, J.N., Ye, L., Libri, V., Leppert,D. and Beach, T.G. PIB is a non-specific imaging marker of amyloid-beta (Abeta)peptide-related cerebral amyloidosis. Brain. 2007 Oct;130(Pt 10):2607-261110. Bychkov ER, Gurevich VV, Joyce JN, Benovic JL, Gurevich EV. Elevated expression ofarrestins and G protein-coupled receptor kinases in the striatum of Parkinson’s patientswith concomitant dementia. Neurobiol Aging. 2008 Mar;29(3):379-96.11. Yoshimoto K, Nishimura A, Hattori H, Joyce JN, Yoshida T, Hioki C, Kogure A, UedaS. In vivo brain microdialysis studies on the striatal dopamine and serotonin release inzitter mutant rats. Mech Ageing Dev. 2006 Jul;127(7):628-3212. Nakadate K, Noda T, Sakakibara SI, Kumamoto K, Matsuura T, Joyce JN, Ueda S.Progressive dopaminergic neurodegeneration of substantia nigra in the zitter mutant rat.Acta Neuropathol (Berl). 2006 Jul;112(1):64-7313. Ueda S, Sakakibara S, Nakadate K, Noda T, Shinoda M, Joyce JN. Degeneration ofdopaminergic neurons in the substantia nigra of zitter mutant rat and protection bychronic intake of Vitamin E. Neurosci Lett. 2005 Jun 3;380(3):252-614. Joyce, J.N., Woolsey, C., Ryoo, H., Borwege, S., Hagner, D. A low dose of pramipexoleis neuroprotective in the MPTP mouse model of Parkinson’s disease, and acts todownregulate the dopamine transporter via the D 3 receptor. BMC Biology 2004, 2:22.15. Presgraves, S., Borwege, S., Millan, M. J. and Joyce, J.N. Neuroprotective effects ofS32504 and pramipexole against 1-methyl-4-phenylpyridinium (MPP+) in terminallydifferentiated SH-SY5Y cells are mediated by the D 3 receptor and BDNF dependentpathways. Experimental Neurology, 190(1):157-170.16. Dluzen, D.E., McDermott, J.L., Anderson, L.I., Kucera, J., Joyce, J.N., Osredkar, T.,Walro, J.M. Age-related changes in nigrostriatal dopaminergic function are accentuated10
Jeffrey N. Joyce, Ph.D. December 2012in +/- brain derived neurotrophic factor mice. Neuroscience, 128:201-208, 2004.17. Presgraves, S., Ahmed, T., Borwege, S. and Joyce, J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamineagonists. Neurotoxicity Research, 5(8):579-598, 2004.18. Neisewander, J.L., Fuchs, R.A., Tran-Nguyen, L.T.L., Weber, S.M., Coffey, G.P. andJoyce, J.N. Abstinence from a cocaine self-administration regimen in rats increasesdopamine D 3 receptor binding: Implications for understanding cocaine-seeking behavior.Neuropsychopharmacology, 29(8):1479-87., 2004.19. Millan, M.J., Di Cara, B., Hill, M., Jackson, M., Joyce, J.N., Brotchie, J., McGuire, S.,Crossman, A., Jenner, P., Gobert, A., Peglion, J.-L. and Brocco, M. S3504, a novelnaphtoxazine agonist at D3/D2 receptors: II. Actions in rodent, primate and cellularmodels of antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther2004;309 921-935.20. Joyce, J.N. Der, T.C., Renish, L, Osredkar, T., Hagner, D., Reploge, M, Sakakibara, S.,and Ueda, S. Loss of D 3 receptors in the zitter mutant rat is not reversed by L-dopatreatment. Exp. Neurol., 187/1: 178-189, 2004.21. Joyce, J.N., Renish, L. Osredkar, T., Walro, J.M., Kucera, J. and Dluzen, D.E.Methamphetamine induced loss of striatal dopamine innervation in BNDF heterozygotemice does not further alter D 3 receptor concentrations. Synapse, Volume 52, Issue 1(April 2004): 11-19. DOI: 10.1002/syn.10309.22. Beach TG, Walker DG, Sue LI, Newell A, Adler CH, and Joyce J.N. Substantia NigraMarinesco Bodies are associated with decreased striatal expression of dopaminergicmarkers. J Neuropathol Exp Neurol. 2004 Apr; 63(4):329-37.23. Iarkov, A., Hagner, D., Reploge, M., Joyce, J.N. Behavioral effects of dopamine agonistsin MPTP lesioned D 3 receptor knockout mice. Pharmacol Biochem Behav, Vol 76/3-4 pp551-562, 2003 (DOI: 10.1016/j.pbb.2003.09.011).24. Joyce, J.N. Presgraves, S., Renish, L,. Borwege, B., Hagner, D, Osredkar, T, Replogle,M, Paz Soldán, M. M., Millan, M.J. Neuroprotective effects of the novel D3/D2 receptoragonist and anitparkinson agent S32504, in vitro against 1-methyl-4-phenylpyridinium(MPP+)and in vivo against 1-methyl- 4-phenyl-1,2,2,6-tetrahydropyridine (MPTP):acomparison to ropinirole. Exp. Neurol., 184/1 pp. 393-407, 2003. (DOI 10.1016/S0014-4886(03)00353-4).25. Joyce, J.N., H. Ryoo, T. B. Beach, J. N. Caviness, M. Stacy, E. V. Gurevich, M. Reiser,C. H. Adler. Loss of clinical response to levo-dopa in Parkinson’s disease and cooccurrencewith dementia: role of D3 and not D2 receptor. Brain Res. 955:138-152,2002.26. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normalaging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease:longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism andRelated Disorders, 9:103-110, 2002.11
- Page 1 and 2: Office AddressVice President, Divis
- Page 3 and 4: Jeffrey N. Joyce, Ph.D. December 20
- Page 5 and 6: Jeffrey N. Joyce, Ph.D. December 20
- Page 7 and 8: Jeffrey N. Joyce, Ph.D. December 20
- Page 9: Jeffrey N. Joyce, Ph.D. December 20
- Page 13 and 14: Jeffrey N. Joyce, Ph.D. December 20
- Page 15 and 16: Jeffrey N. Joyce, Ph.D. December 20
- Page 17 and 18: Jeffrey N. Joyce, Ph.D. December 20
- Page 19 and 20: Jeffrey N. Joyce, Ph.D. December 20
- Page 21 and 22: Jeffrey N. Joyce, Ph.D. December 20
- Page 23 and 24: Jeffrey N. Joyce, Ph.D. December 20
- Page 25 and 26: Jeffrey N. Joyce, Ph.D. December 20
<strong>Jeffrey</strong> N. <strong>Joyce</strong>, Ph.D. December 20<strong>12</strong>dopamine D 3 receptor knock out mice but suppression by dopamine D 3 /D 2 antagonistsdoes not occur through the dopamine D 3 receptor. In Press, European Journal <strong>of</strong>Pharmacology, Volume 627, Issues 1-3, 10 February 2010, Pages 167-172 .5. Duka, T., Duka,V. <strong>Joyce</strong>, J.N. <strong>and</strong> Sidhu, A. Alpha-synuclein induces GSK-3β–catalyzed tau phosphorylation in Parkinson’s Disease models. FASEB J. 2009Sep;23(9):2820-2830.6. Kufah1, P.R. Zavala, A.R., Singh, A., Thiel, K.J., Dickey, E.D., <strong>Joyce</strong>, J.N.,Neisew<strong>and</strong>er, J.L c-Fos expression associated with reinstatement <strong>of</strong> cocaine-seekingbehavior by response-contingent conditioned cues. Synapse. 2009 Oct;63(10):823-835.7. Zavala, A.R., Osredkar, T., <strong>Joyce</strong>, J.N. <strong>and</strong> Neisew<strong>and</strong>er, J.L. Upregulation <strong>of</strong> ArcmRNA expression in the prefrontal cortex following cue-induced reinstatement <strong>of</strong>extinguished cocaine-seeking behavior. Synapse, 2008 Jun;62(6):421-31.8. Mastroeni D, Grover A, Leonard B, <strong>Joyce</strong> JN, Coleman PD, Kozik B, Bellinger DL,Rogers J. Microglial responses to dopamine in a cell culture model <strong>of</strong> Parkinson'sdisease. Neurobiol Aging. 2009 Nov;30(<strong>11</strong>):1805-179. Lockhart, A., Lamb, J.R., Osredkar, T., Sue, L.I., <strong>Joyce</strong>, J.N., Ye, L., Libri, V., Leppert,D. <strong>and</strong> Beach, T.G. PIB is a non-specific imaging marker <strong>of</strong> amyloid-beta (Abeta)peptide-related cerebral amyloidosis. Brain. 2007 Oct;130(Pt 10):2607-26<strong>11</strong>10. Bychkov ER, Gurevich VV, <strong>Joyce</strong> JN, Benovic JL, Gurevich EV. Elevated expression <strong>of</strong>arrestins <strong>and</strong> G protein-coupled receptor kinases in the striatum <strong>of</strong> Parkinson’s patientswith concomitant dementia. Neurobiol Aging. 2008 Mar;29(3):379-96.<strong>11</strong>. Yoshimoto K, Nishimura A, Hattori H, <strong>Joyce</strong> JN, Yoshida T, Hioki C, Kogure A, UedaS. In vivo brain microdialysis studies on the striatal dopamine <strong>and</strong> serotonin release inzitter mutant rats. Mech Ageing Dev. 2006 Jul;<strong>12</strong>7(7):628-32<strong>12</strong>. Nakadate K, Noda T, Sakakibara SI, Kumamoto K, Matsuura T, <strong>Joyce</strong> JN, Ueda S.Progressive dopaminergic neurodegeneration <strong>of</strong> substantia nigra in the zitter mutant rat.Acta Neuropathol (Berl). 2006 Jul;<strong>11</strong>2(1):64-7313. Ueda S, Sakakibara S, Nakadate K, Noda T, Shinoda M, <strong>Joyce</strong> JN. Degeneration <strong>of</strong>dopaminergic neurons in the substantia nigra <strong>of</strong> zitter mutant rat <strong>and</strong> protection bychronic intake <strong>of</strong> Vitamin E. Neurosci Lett. 2005 Jun 3;380(3):252-614. <strong>Joyce</strong>, J.N., Woolsey, C., Ryoo, H., Borwege, S., Hagner, D. A low dose <strong>of</strong> pramipexoleis neuroprotective in the MPTP mouse model <strong>of</strong> Parkinson’s disease, <strong>and</strong> acts todownregulate the dopamine transporter via the D 3 receptor. BMC Biology 2004, 2:22.15. Presgraves, S., Borwege, S., Millan, M. J. <strong>and</strong> <strong>Joyce</strong>, J.N. Neuroprotective effects <strong>of</strong>S32504 <strong>and</strong> pramipexole against 1-methyl-4-phenylpyridinium (MPP+) in terminallydifferentiated SH-SY5Y cells are mediated by the D 3 receptor <strong>and</strong> BDNF dependentpathways. Experimental Neurology, 190(1):157-170.16. Dluzen, D.E., McDermott, J.L., Anderson, L.I., Kucera, J., <strong>Joyce</strong>, J.N., Osredkar, T.,Walro, J.M. Age-related changes in nigrostriatal dopaminergic function are accentuated10
Change language